로딩 중…
지수 로딩 중…
ARS Pharmaceuticals, Inc.
SPRY· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$3.05-9.76%
2026-11-02
Financials
Valuation Metrics
ARS Pharmaceuticals, Inc.'s Market Cap is $303M. At end of 2025 it was $1.15B. Ranked #2801 of 3,114 in US market (top 90%), #1232 of 1,469 on NASDAQ (top 84%), #222 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $303M | US#2,801/3,114 Sec#222/265 |
| Revenue | $117M | US#2,648/3,114 Sec#120/265 |
| Net Income | $-215M | US—/3,114 Sec—/265 |
| Total Assets | $249M | US#2,945/3,114 Sec#228/265 |
| Net Assets | $13M | US#2,897/3,114 Sec#236/265 |
| Employees | 163 | US#2,518/3,114 Sec#137/265 |
| Value | ||
| P/B | 24.21x | US#2,861/3,114 Sec#228/265 |
| P/S | 2.59x | US#1,973/3,114 Sec#62/265 |
| FCF Yield | -64.91% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROA | -86.35% | US#3,046/3,114 Sec#250/265 |
| Op. Margin | -184.96% | US#2,742/3,114 Sec#134/265 |
| Revenue Growth | 4.08% | US#1,851/3,114 Sec#119/265 |
| Financial Health | ||
| Debt Ratio | 1894.05% | US#2,837/3,114 Sec#233/265 |
| Total Debt | $172M | US#2,290/3,114 Sec#98/265 |
| FCF | $-197M | US#2,784/3,114 Sec#209/265 |
| Cash | $8M | US#2,991/3,114 Sec#263/265 |
| Current Ratio | 3.48x | US#652/3,114 Sec#171/265 |
| Performance | ||
| 1Y Return | -65.96% | US#2,940/3,114 Sec#242/265 |
| 1M Return | -25.06% | US#1,830/3,114 Sec#96/265 |
| From 52W High | -76.81% | US#2,937/3,114 Sec#237/265 |
| 1Y MDD | -76.65% | US#2,927/3,114 Sec#235/265 |
| Trading | ||
| Volume | 1,900,430 shares | US#1,065/3,114 Sec#87/265 |
| Trading Value | $6M | US#2,429/3,114 Sec#190/265 |
| Per Share | ||
| EPS | $-2.17 | US—/3,114 Sec—/265 |
| BPS | $0.13 | US#2,787/3,114 Sec#229/265 |
Company Info
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.